Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-19T06:10:24.713Z Has data issue: false hasContentIssue false

Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography

Published online by Cambridge University Press:  18 September 2015

C. Nahmias
Affiliation:
Department of Nuclear Medicine, McMaster University Medical Centre, Hamilton, Ontario
G. Firnau
Affiliation:
Department of Nuclear Medicine, McMaster University Medical Centre, Hamilton, Ontario
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

[18F] 6-fluoro-L-dopa and positron emission tomography has been used to study intracerebral dopamine distribution in five control subjects and six patients with hemiparkinsonism. In the control subjects striatal, frontal and cingulate accumulations were clearly seen. In addition 18F concentrated in the region of the insula and the parietal lobe.

In the patients striatal accumulation 18F was reduced in the contralateral striatum, especially in the putamen. The uniformity of distribution of 18F in the striatum on the side of the parkinsonian signs was also irregular. This finding is consonant with the suggestion that intracerebral compensatory mechanisms prevent the manifestation of intracerebral dopamine deficiency from becoming obvious until a late stage of the disease.

Type
5. Positron Emission Tomography in Parkinson’s Disease
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Firnau, G, Garnett, ES, Sourkes, TL, Missala, K (1975) [18F]Fluoro-dopa: a unique gamma emitting substrate for dopa decarboxylase. Experientia, 31: 12541255.CrossRefGoogle Scholar
Firnau, G, Chirakal, R, Sood, S, Garnett, ES (1981) Radiofluorination with Xenon difluoride: L-6 [18F]fluorodopa. J Labelled Com. Radiopharm., 18: 78.Google Scholar
Garnett, ES, Firnau, G, Nahmias, C, Chirakal, R (1983) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 280: 169171.CrossRefGoogle ScholarPubMed
Garnett, ES, Firnau, G, Nahmias, C (1983) Dopamine visualised in the basal ganglia of living man. Nature, 305: 137138.CrossRefGoogle ScholarPubMed
Hokfelt, T, Ungerstedt, U (1974) The degeneration patterns of the nigro-striatal dopamine system after electrothermic or6-hydroxydopamine lesions. In Dynamics of Degeneration and Growth in Neurons. Ed. Fuxe, K., Olson, L., Zotterman, Y.. Pergammon Press, Oxford.Google Scholar
Hornykiewicz, O (1980) Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson’s disease. In Parkinson’s disease; current progress, problems and management. Eds. Rinne, U.K., Klingler, M., Stamm, G., Elsevier, Amsterdam.Google Scholar
Hornykiewicz, O (1982) Brain neurotransmitter changes in Parkinson’s disease. In Movement Disorders. Eds. Marsden, CD. and Fahn, S.. Butterworth Scientific, London.Google Scholar
Lee, T, Seeman, P, Rajput, Aet al. (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 5961.CrossRefGoogle ScholarPubMed
Leenders, K, Wolfson, L, Gibbs, J, Wise, R, Jones, T, Legg, N (1983) Regional cerebral blood flow and oxygen metabolism in Parkinson’s disease and their response to L-dopa. J. Cereb. Blood Flow Metab., 3: Suppl. 488489.Google Scholar
Lloyd, KG, Hornykiewicz, O (1972) Occurrence and distribution of aromatic acid (L-dopa) decarboxylase in human brain. J. Neurochem. 19: 15491559.CrossRefGoogle ScholarPubMed
Lenzi, GL, Jones, T, Reid, J, Moss, S (1977) Non-invasive study of the metabolism to blood flow relationship in Parkinson’s disease. Acta. Neurol Scand., 56, Suppl. 64: 184185.Google Scholar
Nahmias, C, Firnau, G, Garnett, ES (1984) Performance characteristics of the McMaster Positron Emission Tomograph. IEEE, NS-31, (in press).CrossRefGoogle Scholar
Rougemont, D, Baron, JC, Collard, P, Bustany, P, Colmar, D, Agid, Y (1983) Local cerebal metabolic rate of glucose (CMR G) in treated and untreated patients with Parkinson’s disease. J. Cereb. Blood Flow Metab. 3, Suppl. 1: 504505.Google Scholar
Wiesel, FA, Fri, CG, Sedvall, G (1973) Determination of homovanillic acid turnover in rat striatum using a monoamine oxidase inhibitor. Eur. J. Pharamacol. 23: 104106.CrossRefGoogle ScholarPubMed
Wooten, GF, Collins, RC (1981) Metabolic effects of unilateral lesion of hte substantia nigra. J. Neurosci. 1: 285291.CrossRefGoogle Scholar